CT 海外癌症临床试验导航 公开信息导航，不做医疗判断

海外临床试验导航

白血病

帮助用户按 AML、ALL、CLL、CML、复发难治、MRD、靶向和细胞治疗等方向检索海外公开临床试验。

中文医学标准名
白血病
英文医学标准名
Leukemia
试验数据最后同步
2026-07-10

Synced trials

当前同步到的治疗类试验

以下记录来自公开临床试验数据库，已按招募状态、治疗目的、干预类型和癌症相关性做初步过滤。本站不判断患者是否符合入组条件，请以官方页面、医生和研究团队意见为准。

最后同步日期：2026-07-10 · 当前显示 1061 条

招募状态和入组条件可能随时变化。请以官方页面、医院和研究机构信息为准，并带给主治医生或肿瘤科医生讨论。

状态
全部
试验阶段
全部
治疗类型
全部
国家/地区
全部
正在招募 阶段未标明 生物制剂
clinicaltrials.gov NCT06885476

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

适用疾病
Acute Myeloid Leukemia；Minimal Residual Disease；Natural Killer Cell
干预
Infusion of alloreactive NK cells
地点
Italy
申办方
IRCCS Azienda Ospedaliero-Universitaria di Bologna
正在招募 Phase 1 药物其他
clinicaltrials.gov NCT07321626

Romiplostim N01 for Platelet Recovery After Haploidentical HSCT

适用疾病
Acute Myeloid Leukemia；MDS (Myelodysplastic Syndrome)；Delayed Platelet Engraftment
干预
Romiplostim N01，Standard Supportive Care
地点
China
申办方
First Affiliated Hospital of Zhejiang University
即将招募 Phase 2 联合产品药物
clinicaltrials.gov NCT07562568

SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS

适用疾病
Acute Myeloid Leukemia；Acute Lymphoblastic Leukemia；MDS
干预
SHR2554/AZA + Overlapped TBF，mBUCY conditioning regimen
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT06247787

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

适用疾病
Recurrent Childhood Acute Myeloid Leukemia；Recurrent Childhood Myelodysplastic Syndrome；Recurrent Juvenile Myelomonocytic Leukemia
干预
Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Cytarabine
地点
United States
申办方
Children's Oncology Group
正在招募 Phase 2 药物
clinicaltrials.gov NCT05521204

Olverembatinib for FGFR1-rearranged Neoplasms

适用疾病
Myeloproliferative Neoplasm；Acute Leukemia
干预
Olverembatinib
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 1, Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT06928662

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

适用疾病
Acute Myeloid Leukemia；Acute Undifferentiated Leukemia；Mixed Phenotype Acute Leukemia
干预
Decitabine，Bone Marrow Aspiration，Bone Marrow Biopsy，Chest Radiography
地点
United States
申办方
Fred Hutchinson Cancer Center
正在招募 Phase 1 药物
clinicaltrials.gov NCT05317403

Venetoclax to Augment Epigenetic Modification and Chemotherapy

适用疾病
Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory
干预
Venetoclax，Azacitadine，Vorinostat，Cytarabine
地点
United States
申办方
Medical College of Wisconsin
正在招募 Phase 1 药物
clinicaltrials.gov NCT06313437

Revumenib in Combination With 7+3 + Midostaurin in AML

适用疾病
Acute Myeloid Leukemia；AML, Adult；AML With Gene Mutations
干预
Revumenib，Midostaurin，Cytarabine，Daunorubicin
地点
United States
申办方
Richard Stone, MD
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT04140487

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

适用疾病
Recurrent Acute Myeloid Leukemia；Recurrent Chronic Myelomonocytic Leukemia；Recurrent Myelodysplastic/Myeloproliferative Neoplasm
干预
Azacitidine，Gilteritinib，Venetoclax
地点
United States
申办方
M.D. Anderson Cancer Center
正在招募 Phase 2 生物制剂药物
clinicaltrials.gov NCT05884333

Cord Blood Transplant in Adults With Blood Cancers

适用疾病
Acute Myelogenous Leukemia (AML)；Acute Lymphoblastic Leukemia (ALL)；Chronic Myelogenous Leukemia (CML)
干预
Conditioning Chemotherapy，Cord blood graft
地点
United States
申办方
Memorial Sloan Kettering Cancer Center
正在招募 Phase 1 药物
clinicaltrials.gov NCT06372717

A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS

适用疾病
Acute Myeloid Leukemia Refractory；Myelodysplastic Syndrome Acute Myeloid Leukemia；Myelodysplastic Syndrome With Excess Blasts
干预
APL-4098，Azacitidine and APL-4098，Azacitidine and Venetoclax and APL-4098
地点
Australia，United Kingdom
申办方
Apollo Therapeutics Ltd
正在招募 阶段未标明 药物其他
clinicaltrials.gov NCT06232694

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML

适用疾病
Acute Myeloid Leukemia
干预
Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;，Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;，utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).
地点
China
申办方
The First Affiliated Hospital with Nanjing Medical University
即将招募 Phase 2 药物
clinicaltrials.gov NCT06987058

RVU120 Rollover Study

适用疾病
Advanced Solid Tumors；Acute Myeloid Leukaemia (AML)；High-risk Myelodysplastic Syndrome
干预
RVU120
地点
Poland，Spain
申办方
Ryvu Therapeutics SA
正在招募 Phase 1, Phase 2 生物制剂药物
clinicaltrials.gov NCT07591649

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

适用疾病
Relapsed Adult AML；Refractory AML；Acute Myelogenous Leukemia
干预
AdaptNK，Fludarabine，Cyclophosphamide，IL-2
地点
United States
申办方
Masonic Cancer Center, University of Minnesota
正在招募 Phase 1 药物手术/操作
clinicaltrials.gov NCT06222580

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

适用疾病
Acute Myeloid Leukemia With FLT3/ITD Mutation；Acute Myeloid Leukemia With KMT2A Rearrangement；Acute Myeloid Leukemia With NPM1 Mutation
干预
Biospecimen Collection，Bone Marrow Aspiration and Biopsy，Gilteritinib，Revumenib
地点
United States
申办方
Uma Borate
正在招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT07366801

Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies

适用疾病
Acute Myeloid Leukemia, Relapsed；Acute Lymphoblastic Leukemia, High Risk；Acute Myeloid Leukemia, High Risk
干预
Cyclosporine A (CsA)，Sirolimus，Ruxolitinib (JAKAVI®)，Abatacept
地点
Russia
申办方
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
正在招募 Phase 1 生物制剂
clinicaltrials.gov NCT05995041

Universal CAR-T Cells Targeting AML

适用疾病
Acute Myeloid Leukemia
干预
CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
地点
China
申办方
Shenzhen Geno-Immune Medical Institute
正在招募 Phase 2 药物
clinicaltrials.gov NCT07007949

a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia

适用疾病
Acute Myeloid Leukemia；IDH1 Gene Mutation；Ivosidenib
干预
Ivosidenib combined with venetoclax and azacitidine，Ivosidenib combined with venetoclax and azacitidine
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 2 药物
clinicaltrials.gov NCT07163793

Pilot Study of Reduced Venetoclax Exposure

适用疾病
Acute Myeloid Leukemia in Remission
干预
Azacitidine，Decitabine，Venetoclax
地点
United States
申办方
Northwell Health
正在招募 Phase 2 生物制剂药物
clinicaltrials.gov NCT03263572

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

适用疾病
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive；Acute Lymphoblastic Leukemia；BCR-ABL1 Fusion Protein Expression
干预
Blinatumomab，Cytarabine，Methotrexate，Ponatinib
地点
United States
申办方
M.D. Anderson Cancer Center
即将招募 Phase 2 药物
clinicaltrials.gov NCT07449286

IFN-α in Relapse Prevention.

适用疾病
Acute Myeloid Leukemia；Myelodysplastic Syndromes
干预
IFN-α
地点
China
申办方
Peking University People's Hospital
正在招募 Phase 2 药物其他
clinicaltrials.gov NCT05788679

A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS

适用疾病
Myelodysplastic Syndromes；Acute Myeloid Leukemia With Myelodysplasia Related Disease and < 30% Blasts；Mixed Myelodysplastic/Myeloproliferative Disease
干预
Azacitidine，Donor lymphocytes，Tapering of immune suppression
地点
Sweden
申办方
Karolinska University Hospital
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT03850574

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

适用疾病
Leukemia, Myeloid, Acute；Refractory AML；Relapsed Adult AML
干预
Tuspetinib，Venetoclax Oral Tablet，Azacitidine for Intravenous Infusion
地点
United States，Australia，Germany，New Zealand 等 2 个
申办方
Aptose Biosciences Inc.
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT05092451

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

适用疾病
B-Cell Lymphoma；Myelodysplastic Syndromes (MDS)；Acute Myeloid Leukemia (AML)
干预
Cyclophosphamide，CAR.70/IL15-transduced CB-NK cells，Fludarabine phosphate
地点
United States
申办方
M.D. Anderson Cancer Center
即将招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT07425808

FLT3-ITD Targeted Therapy in Fit AML Patients

适用疾病
AML (Acute Myeloid Leukemia)
干预
Gilteritinib，Venetoclax，Azacitidine (AZA)，Local standard of care (SOC)
地点
未列出
申办方
European Organisation for Research and Treatment of Cancer - EORTC
即将招募 阶段未标明 药物
clinicaltrials.gov NCT07644481

Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission

适用疾病
AML (Acute Myelogenous Leukemia)；Allogeneic Hematopoietic Stem Cell Transplantation Recipient
干预
CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen
地点
未列出
申办方
Institute of Hematology & Blood Diseases Hospital, China
正在招募 Phase 2 药物
clinicaltrials.gov NCT06532084

Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen

适用疾病
Acute Myeloid Leukemia, in Relapse；Myelodysplastic Syndromes；Chronic Myeloid Leukemia
干预
Sorafenib
地点
Russia
申办方
St. Petersburg State Pavlov Medical University
正在招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT06788756

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

适用疾病
Acute Myeloid Leukaemia (AML)
干预
Placebo in combination with Cytarabine Injection，Liposomal Annamycin Injection in combination with Cytarabine Injection，Liposomal Annamycin Injection in combination with Cytarabine Injection，Liposomal Annamycin for Injection in combination with Cytarabine Injection.
地点
United States，Georgia，Italy，Lithuania 等 4 个
申办方
Moleculin Biotech, Inc.
正在招募 Phase 2 药物
clinicaltrials.gov NCT06477549

BeFluBu vs FluBuRux Conditioning in Haploidentical HCT

适用疾病
Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Biphenotypic Acute Leukemia
干预
Bendamustine Hydrochloride，Ruxolitinib
地点
Russia
申办方
St. Petersburg State Pavlov Medical University
即将招募 Phase 3 药物
clinicaltrials.gov NCT06613035

Twice-per-weekSelinexor, 2 Days Melphalan

适用疾病
Acute Myeloid Leukemia
干预
Selinexor，Melphalan，Intravenous Busulfan，Fludarabine
地点
China
申办方
Institute of Hematology & Blood Diseases Hospital, China
正在招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT04256317

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

适用疾病
Myelodysplastic Syndromes；Acute Myeloid Leukemia；Myelodysplastic Syndrome/Neoplasm
干预
Azacitidine，ASTX030 (cedazuridine + azacitidine)，Azacitidine，ASTX030 (cedazuridine + azacitidine)
地点
United States，Canada，Czechia，France 等 6 个
申办方
Taiho Oncology, Inc.
正在招募 Phase 2 药物放疗
clinicaltrials.gov NCT06802315

Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)

适用疾病
Acute Myeloid Leukemia, Relapsed, Adult；Acute Myeloid Leukemia Refractory；Chronic Myeloid Leukemia - Accelerated Phase
干预
Intensity modulated total marrow irradiation，Cyclophosphamide (CTX)，Fludarabine (Fludara)，Busulfan (conditioning for ALLO Transplant)
地点
United States
申办方
University of Illinois at Chicago
正在招募 Phase 1 药物
clinicaltrials.gov NCT06594445

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

适用疾病
Myeloid Malignancy；Acute Myeloid Leukemia；Myelodysplastic Syndromes
干预
GTB-360
地点
United States
申办方
Masonic Cancer Center, University of Minnesota
即将招募 Phase 2 药物手术/操作
clinicaltrials.gov NCT05554419

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

适用疾病
Acute Myeloid Leukemia；Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome；Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm
干预
Azacitidine，Bone Marrow Aspiration and Biopsy，Cytarabine，Echocardiography Test
地点
未列出
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 药物其他手术/操作
clinicaltrials.gov NCT06859424

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

适用疾病
AML (Acute Myelogenous Leukemia)；Acute Lymphoid Leukemia (ALL)；Acute Leukemia (Category)
干预
Conditioning Regimen A，Conditioning Regimen B，Conditioning Regimen C，Conditioning Regimen D
地点
United States
申办方
Center for International Blood and Marrow Transplant Research
即将招募 阶段未标明 药物
clinicaltrials.gov NCT07521124

ABC Maintenance Therapy for AML

适用疾病
Acute Myeloid Leukemia (AML) in Remission
干预
Cohort 1 (MRD-Negative Patients): 61 subjects，Cohort 2 (MRD-Persistent Positive Patients): 43 subjects
地点
China
申办方
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
正在招募 Phase 3 药物
clinicaltrials.gov NCT06810791

HVA vs IA/DA or VA in the Treatment of ND HR-AML

适用疾病
Newly Diagnosed Acute Myeloid Leukemia With High Risk
干预
HVA，VA，Standard Chemotherapy
地点
China
申办方
Nanfang Hospital, Southern Medical University
即将招募 Phase 2 生物制剂药物放疗
clinicaltrials.gov NCT07634536

Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant

适用疾病
Acute Myeloid Leukemia；Myeloproliferative Neoplasm；Myelodysplastic Syndromes
干预
VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI)，Fludarabine，Cyclophosphamide，Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)
地点
United States
申办方
Stanford University
正在招募 Phase 1 药物
clinicaltrials.gov NCT07661095

A Study of CRD3874-SI in People With Leukemia

适用疾病
Acute Myeloid Leukemia；AML；Refractory Acute Myeloid Leukemia
干预
CRD3874-SI
地点
United States
申办方
Memorial Sloan Kettering Cancer Center
正在招募 Phase 2 生物制剂药物其他
clinicaltrials.gov NCT02727803

Personalized NK Cell Therapy in CBT

适用疾病
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive；Acute Biphenotypic Leukemia；Acute Lymphoblastic Leukemia
干预
Allogeneic Natural Killer Cell Line NK-92，Anti-Thymocyte Globulin，Busulfan，Clofarabine
地点
United States
申办方
M.D. Anderson Cancer Center
正在招募 Phase 1 生物制剂药物
clinicaltrials.gov NCT06152809

CIML NK Cells With Venetoclax for AML

适用疾病
Acute Myeloid Leukemia；Acute Myeloid Leukemia Recurrent；Leukemia
干预
Cytokine-Induced Memory-like Natural Killer Cells，Interleukin-2，Venetoclax
地点
United States
申办方
Dana-Farber Cancer Institute
正在招募 Phase 1 生物制剂手术/操作
clinicaltrials.gov NCT03326921

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

适用疾病
Juvenile Myelomonocytic Leukemia；Recurrent Acute Biphenotypic Leukemia；Recurrent Acute Undifferentiated Leukemia
干预
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR，Bone Marrow Aspiration，Biospecimen Collection
地点
United States
申办方
Fred Hutchinson Cancer Center
正在招募 Phase 1 药物
clinicaltrials.gov NCT02390752

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

适用疾病
Neurofibroma, Plexiform；Precursor Cell Lymphoblastic Leukemia-Lymphoma；Leukemia, Promyelocytic, Acute
干预
TURALIO(R)
地点
United States
申办方
National Cancer Institute (NCI)
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT04375631

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

适用疾病
Recurrent Acute Myeloid Leukemia；Recurrent Chronic Myelomonocytic Leukemia；Recurrent Myelodysplastic Syndrome
干预
Cladribine，Cyclophosphamide，Cyclosporine，Cytarabine
地点
United States
申办方
Fred Hutchinson Cancer Center
正在招募 Phase 1 药物
clinicaltrials.gov NCT06835140

CD123-CD16-NK Cells Immunotherapy for AML

适用疾病
AML (Acute Myelogenous Leukemia)；NK Cell；CD123+ Acute Myeloid Leukemia
干预
Donor-derived CD123-CD16 bispecific antibody-modified NK cells
地点
China
申办方
Chunji Gao
正在招募 Phase 1 药物
clinicaltrials.gov NCT05292664

Venetoclax Basket Trial for High Risk Hematologic Malignancies

适用疾病
Myelodysplastic Syndromes, de Novo；Myelodysplastic Syndromes, Secondary；Myelodysplastic Syndromes, Previously Treated
干预
Venetoclax，Azacitidine，Cytarabine，Methotrexate
地点
United States
申办方
Andrew E. Place, MD
正在招募 阶段未标明 药物
clinicaltrials.gov NCT07244367

Maintenance Venetoclax in AML Fit Patients

适用疾病
Acute Myeloid Leukaemia (AML)
干预
SC cytarabine +Venetoclax
地点
Egypt
申办方
Sohag University
正在招募 Phase 1 药物手术/操作
clinicaltrials.gov NCT05886049

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

适用疾病
Acute Myeloid Leukemia；Acute Myeloid Leukemia With KMT2A Rearrangement；Acute Myeloid Leukemia With NPM1 Mutation
干预
Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Cytarabine
地点
United States
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 药物
clinicaltrials.gov NCT04050280

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

适用疾病
Acute Myeloid Leukemia, Adult；Acute Myeloid Leukemia Recurrent；Acute Myeloid Leukemia, Relapsed, Adult
干预
Cladribine, Cytarabine, and Granulocyte-Colony Stimulating Factor with Fractionated Gemtuzumab Ozogamicin (CLAG-GO)
地点
United States
申办方
University of Maryland, Baltimore
正在招募 Phase 2 药物
clinicaltrials.gov NCT04996875

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

适用疾病
Advanced Systemic Mastocytosis (AdvSM)；SM With an Associated Hematologic Neoplasm (SM-AHN)；Mast Cell Leukemia (MCL)
干预
bezuclastinib
地点
United States，Australia，Austria，Belgium 等 10 个
申办方
Cogent Biosciences, Inc.
正在招募 Phase 2 药物
clinicaltrials.gov NCT06508099

Vitamin A and D Supplementation in Allogeneic HCT

适用疾病
Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Biphenotypic Acute Leukemia
干预
Vitamin A，Vitamin D3
地点
Russia
申办方
St. Petersburg State Pavlov Medical University
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT06287944

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

适用疾病
Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Myelodysplastic Syndrome
干预
Actinium Ac 225-DOTA-Daratumumab，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点
United States
申办方
City of Hope Medical Center
即将招募 Phase 2, Phase 3 生物制剂药物
clinicaltrials.gov NCT07623187

A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy

适用疾病
Acute Myeloid Leukaemia (AML)；Acute Myeloid Leukaemia
干预
IPN60340 + azacitidine + venetoclax，Placebo + azacitidine + venetoclax
地点
未列出
申办方
Ipsen
正在招募 Phase 1 药物
clinicaltrials.gov NCT07617285

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

适用疾病
AML；Refractory/Relapse Acute Myeloid Leukemia
干预
CAR-T cells chimeric antigen receptor T cells
地点
China
申办方
Peking University People's Hospital
正在招募 Phase 1 药物
clinicaltrials.gov NCT03595917

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

适用疾病
B-cell Acute Lymphoblastic Leukemia；Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis；Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
干预
ABL001，Dasatinib，Prednisone，Blinatumomab
地点
United States
申办方
Marlise Luskin, MD
正在招募 Phase 2 生物制剂药物其他
clinicaltrials.gov NCT00801489

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

适用疾病
Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11；Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11；Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
干预
Cytarabine，Decitabine，Filgrastim-sndz，Fludarabine Phosphate
地点
United States
申办方
M.D. Anderson Cancer Center
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT05211570

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

适用疾病
Acute Myeloid Leukemia Refractory；Acute Myeloid Leukemia, in Relapse；Myelodysplastic Syndrome Acute Myeloid Leukemia
干预
AB8939，Venetoclax
地点
United States，France，Greece，Spain
申办方
AB Science
正在招募 Phase 2 药物
clinicaltrials.gov NCT04687176

Frontline Oral Arsenic Trioxide for APL

适用疾病
Acute Promyelocytic Leukemia
干预
Oral Arsenic Trioxide Formulation
地点
Hong Kong，Singapore
申办方
The University of Hong Kong
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT03017820

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

适用疾病
B-Cell Non-Hodgkin Lymphoma；Histiocytic and Dendritic Cell Neoplasm；Myelodysplastic Syndrome
干预
Biopsy Procedure，Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography
地点
United States
申办方
Mayo Clinic
正在招募 Phase 1 药物
clinicaltrials.gov NCT06440135

Ziftomenib Maintenance Post Allo-HCT

适用疾病
Acute Myeloid Leukemia；Acute Myeloid Leukemia in Remission；NPM1 Mutation
干预
Ziftomenib
地点
United States
申办方
Massachusetts General Hospital
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT07166419

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

适用疾病
Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive；Recurrent Acute Lymphoblastic Leukemia；Recurrent Chronic Lymphocytic Leukemia
干预
Autologous Anti-CD19/CD20/CD22 CAR T-cells，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点
United States
申办方
Ohio State University Comprehensive Cancer Center
正在招募 Phase 1 药物手术/操作
clinicaltrials.gov NCT05627232

Tazemetostat and Palbociclib With CPX-351for R/R AML

适用疾病
Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia
干预
Tazemetostat，Liposome-encapsulated Daunorubicin-Cytarabine，Bone Marrow Aspiration and Biopsy，Biospecimen Collection
地点
United States
申办方
Thomas Jefferson University
即将招募 Phase 2 药物手术/操作放疗
clinicaltrials.gov NCT06954987

Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

适用疾病
Acute Myeloid Leukemia
干预
Allogeneic Hematopoietic Stem Cell Transplantation，Biospecimen Collection，Bone Marrow Biopsy，Busulfan
地点
未列出
申办方
National Cancer Institute (NCI)
正在招募 Phase 1 药物手术/操作
clinicaltrials.gov NCT06484062

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

适用疾病
Acute Myeloid Leukemia；Myelodysplastic Syndrome；Myelodysplastic Syndrome/Acute Myeloid Leukemia
干预
Biospecimen Collection，Bone Marrow Aspiration，Cirtuvivint，Decitabine and Cedazuridine
地点
United States
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 药物
clinicaltrials.gov NCT06707493

Ivosidenib as Post-HSCT Maintenance for AML

适用疾病
IDH1 Mutation；Acute Myeloid Leukemia (AML)；Hematopoietic Stem Cell Transplant (HSCT)
干预
Ivosidenib，Placebo
地点
United States
申办方
Massachusetts General Hospital
正在招募 Phase 2 药物
clinicaltrials.gov NCT06778187

Oral-ATO for TP53-mutated Myeloid Malignancies

适用疾病
Acute Myeloid Leukemia；Myelodysplastic Neoplasm；Chronic Myelomonocytic Leukemia
干预
Oral arsenic trioxide
地点
Hong Kong
申办方
The University of Hong Kong
正在招募 Phase 1, Phase 2 生物制剂药物
clinicaltrials.gov NCT06680752

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

适用疾病
Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory；MDS (Myelodysplastic Syndrome)
干预
ARD103，Cyclophosphamide，Fludarabine
地点
United States
申办方
ARCE Therapeutics, Inc.
正在招募 Phase 3 药物
clinicaltrials.gov NCT07232134

The Efficacy of Therapy in Patients With Acute Myeloid Leukemia and Down Syndrome in Russia

适用疾病
AML (Acute Myelogenous Leukemia)；Down Syndrome (DS)
干预
4 chemotherapy blocks: Course 1 AIE (cytarabine/idarubicin/etoposide), Course 2 AI (cytarabine/idarubicin), Course 3 HAD (high-dose cytarabine (1g)/daunorubicin), Course 4 HA (high-dose cytarabine).
地点
Russia
申办方
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
正在招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT06424340

MB-dNPM1-TCR.1 in Relapsed/Refractory AML

适用疾病
Leukemia, Myeloid, Acute
干预
MB-dNPM1-TCR.1
地点
Netherlands
申办方
Miltenyi Biomedicine GmbH
正在招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT03222674

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

适用疾病
Acute Myeloid Leukemia
干预
Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells
地点
China
申办方
Shenzhen Geno-Immune Medical Institute
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT04771130

A Study of BGB-11417 in Participants With Myeloid Malignancies

适用疾病
Acute Myeloid Leukemia；Myelodysplastic Syndromes；Myelodysplastic/Myeloproliferative Neoplasm
干预
BGB-11417，Azacitidine，Posaconazole，BGB-11417
地点
United States，Australia，China，France 等 6 个
申办方
BeiGene
正在招募 Phase 1 药物
clinicaltrials.gov NCT06307054

CLL-1 CAR-NK Cells for Relapsed/Refractory AML

适用疾病
Relapsed Adult AML；Refractory AML
干预
anti-CLL-1 CAR NK cells
地点
China
申办方
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
正在招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT05939180

VA vs DA for Newly Diagnosed Hig-risk AML

适用疾病
Acute Myeloid Leukemia
干预
Venetoclax Oral Tablet，Daunorubicin
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT07523555

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

适用疾病
Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia；Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL；Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
干预
Autologous CD19/CD22 dual-target CAR-T module，Autologous CD19/CD20 dual-target CAR-T module，Autologous BCMA/CD19 dual-target CAR-T module，Autologous BCMA/CD38 dual-target CAR-T module
地点
China
申办方
Beijing Biotech
正在招募 Phase 1, Phase 2 药物手术/操作放疗
clinicaltrials.gov NCT03128034

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

适用疾病
Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome；Acute Myeloid Leukemia
干预
Cyclosporine，Fludarabine Phosphate，Mycophenolate Mofetil，Peripheral Blood Stem Cell Transplantation
地点
United States
申办方
Fred Hutchinson Cancer Center
即将招募 Phase 2 药物放疗
clinicaltrials.gov NCT05565105

CD34+ Transplants for Leukemia and Lymphoma

适用疾病
Leukemia, Myeloid, Acute；Leukemia, Lymphocytic, Acute
干预
Total Body Irradiation (TBI)，Thiotepa，Cyclophosphamide，Busulfan
地点
United States
申办方
Guenther Koehne
即将招募 Phase 3 药物
clinicaltrials.gov NCT07469046

VAH vs VA in Newly Diagnosed Elderly AML

适用疾病
Acute Myeloid Leukemia (AML)；Elderly Patients (60-75 Years)
干预
Venetoclax，Azacitidine，Homoharringtonine
地点
China
申办方
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT07663864

Luspatercept for CIA in AML

适用疾病
Chemotherapy-inducing Anemia
干预
Luspatercept Injectable Product
地点
China
申办方
Guangdong Second Provincial General Hospital
正在招募 Phase 1 药物
clinicaltrials.gov NCT04227847

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

适用疾病
Myelodysplastic Syndrome；Acute Myeloid Leukemia
干预
SEA-CD70，azacitidine，Venetoclax
地点
United States，Japan，Netherlands
申办方
Seagen, a wholly owned subsidiary of Pfizer
正在招募 Phase 2 药物手术/操作
clinicaltrials.gov NCT06917911

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

适用疾病
Core Binding Factor Acute Myeloid Leukemia
干预
Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Cytarabine
地点
United States
申办方
National Cancer Institute (NCI)
正在招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT07583888

VABu Conditioning in Elderly AML HSCT

适用疾病
Allogeneic Hematopoietic Stem Cell Transplantation Recipient；Acute Myeloid Leukemia (AML)
干预
VaBU
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT04068597

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

适用疾病
Haematological Malignancy；Acute Myeloid Leukemia；Non Hodgkin Lymphoma
干预
CCS1477，Pomalidomide，Dexamethasone，Azacitidine
地点
United States，France，Spain，Sweden 等 1 个
申办方
CellCentric Ltd.
正在招募 Phase 3 药物
clinicaltrials.gov NCT05477589

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

适用疾病
Acute Myeloid Leukemia (AML) in Remission；Stem Cell Transplantation
干预
busulfan, cyclophosphamide and melphalan, BuCyMel，clofarabine, fludarabine and busulfan, CloFluBu
地点
Belgium，Denmark，Finland，Hong Kong 等 6 个
申办方
Vastra Gotaland Region
正在招募 Phase 1 生物制剂其他
clinicaltrials.gov NCT07551037

Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

适用疾病
Acute Myeloid Leukemia；Personalized Active Immunotherapy；Maintenance Therapy
干预
Active Immunotherapy，after 6 courses of routine consolidation chemotherapy，during 6 courses of routine consolidation chemotherapy
地点
China
申办方
Fujian Medical University Union Hospital
正在招募 Phase 2 生物制剂药物
clinicaltrials.gov NCT02143830

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

适用疾病
Fanconi Anemia；Severe Marrow Failure；Myelodysplastic Syndrome (MDS)
干预
Busulfan，Cyclophosphamide，Fludarabine，rabbit ATG
地点
United States
申办方
Children's Hospital Medical Center, Cincinnati
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT06195891

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome

适用疾病
Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Myelodysplastic Syndrome
干预
Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Dual-Energy Computed Tomography
地点
United States
申办方
City of Hope Medical Center
正在招募 阶段未标明 药物
clinicaltrials.gov NCT07131059

MRD-positive AML Clinical Study

适用疾病
AML, Adult
干预
Ivosidenib，Gilteritinib，Venetoclax，Avapritinib
地点
China
申办方
Institute of Hematology & Blood Diseases Hospital, China
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT04678401

IS-free Treg HaploHCT

适用疾病
Stem Cell Transplant Complications；Graft Vs Host Disease；Myeloid Leukemia, Acute
干预
Radiation，Fludarabine，Thiotepa，Cyclophosphamide
地点
United States
申办方
Dana-Farber Cancer Institute
正在招募 Phase 2 药物手术/操作放疗
clinicaltrials.gov NCT05031897

Two Step Haplo With Radiation Conditioning

适用疾病
Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Adult T-Cell Leukemia/Lymphoma
干预
Fludarabine，Total-Body Irradiation，Donor Lymphocyte Infusion，Cyclophosphamide
地点
United States
申办方
Thomas Jefferson University
正在招募 Phase 1 药物
clinicaltrials.gov NCT06297941

Study of REM-422 in Patients With AML or Higher Risk MDS

适用疾病
Myelodysplastic Syndromes；Higher Risk Myelodysplastic Syndromes；Acute Myeloid Leukemia
干预
REM-422
地点
United States，France
申办方
Remix Therapeutics
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT04581512

Study to Evaluate the Safety and Tolerability of EP0042

适用疾病
Acute Myeloid Leukemia；Chronic Myelomonocytic Leukemia；Myelodysplastic Syndromes
干预
EP0042，Venetoclax，Azacitidine (AZA)
地点
Australia，Netherlands，United Kingdom
申办方
Ellipses Pharma
正在招募 Phase 1, Phase 2 生物制剂药物其他
clinicaltrials.gov NCT03013998

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

适用疾病
Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
干预
Samalizumab (BAML-16-001-S1)，BI 836858 (BAML-16-001-S2)，Laboratory Biomarker Analysis，Daunorubicin (BAML-16-001-S1)
地点
United States
申办方
Beat AML, LLC
正在招募 Phase 2 生物制剂药物放疗
clinicaltrials.gov NCT05805605

Allo HSCT Using RIC and PTCy for Hematological Diseases

适用疾病
Acute Myelogenous Leukemia；Acute Lymphocytic Leukemia；Biphenotypic Acute Leukemia
干预
Peripheral Blood Stem Cell Transplant，Allopurinol 300 MG，Fludarabine，Cyclophosphamide
地点
United States
申办方
Masonic Cancer Center, University of Minnesota
正在招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT06756152

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

适用疾病
Biphenotypic Acute Leukemia；Acute Lymphoblastic Leukemia；Myeloblastic Leukemia
干预
Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150
地点
Russia
申办方
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
正在招募 Phase 2 药物
clinicaltrials.gov NCT05657639

CAV Regimen for R/R AML

适用疾病
Acute Myeloid Leukemia
干预
CAV Regimen，MEC Regimen
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT04033302

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

适用疾病
T-cell Acute Lymphoblastic Leukemia；T-cell Acute Lymphoblastic Lymphoma；Acute Myeloid Leukemia
干预
CD7-specific CAR gene-engineered T cells
地点
China
申办方
Shenzhen Geno-Immune Medical Institute
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT04385290

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

适用疾病
Acute Myeloid Leukemia
干预
MODULE: conventional chemotherapy (Cytarabine+Daunorubicin) in combination with midostaurin+GO，MAGNOLIA-trial: Midostaurin associated with conventional chemotherapy (AraC+DNR)+GO，MAGNOLIA-trial: conventional chemotherapy (AraC+DNR)+GO，MAGMA-trial:GO associated with conventional chemotherapy (AraC+DNR)+Midostaurin
地点
Germany
申办方
Technische Universität Dresden
正在招募 EARLY / Phase 1 药物
clinicaltrials.gov NCT06201247

Off-the-shelf CD123 CAR-NK for R/R AML

适用疾病
Acute Myeloid Leukemia, in Relapse；Acute Myeloid Leukemia Refractory
干预
JD123 injection
地点
China
申办方
Peking University People's Hospital
正在招募 Phase 1, Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT03670966

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

适用疾病
Acute Lymphoblastic Leukemia in Remission；Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome；Acute Myeloid Leukemia in Remission
干预
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10，Cyclophosphamide，Total-Body Irradiation，Peripheral Blood Stem Cell Transplantation
地点
United States
申办方
Fred Hutchinson Cancer Center
正在招募 Phase 1 药物
clinicaltrials.gov NCT05636514

Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS

适用疾病
Myelodysplastic Syndromes；Chronic Myelomonocytic Leukemia；Acute Myeloid Leukemia
干预
Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET，Defactinib
地点
Australia
申办方
Clinical Hub for Interventional Research (CHOIR)
正在招募 Phase 1 生物制剂
clinicaltrials.gov NCT05995028

Universal 4SCAR7U Targeting CD7-positive Malignancies

适用疾病
T-cell Acute Lymphoblastic Leukemia；T-cell Acute Lymphoblastic Lymphoma；Acute Myeloid Leukemia
干预
Universal CD7-specific CAR gene-engineered T cells
地点
China
申办方
Shenzhen Geno-Immune Medical Institute
即将招募 Phase 1 生物制剂
clinicaltrials.gov NCT07616089

Phase I Study of FXS0683 in the Treatment of Blood Tumors

适用疾病
B-Cell Lymphoma；Acute Myeloid Leukemia；Myelodysplastic Syndromes
干预
FXS0683
地点
China
申办方
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT06059391

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

适用疾病
Acute Lymphoblastic Leukemia；Acute Myeloid Leukemia；Chronic Lymphocytic Leukemia
干预
Allogeneic Hematopoietic Stem Cell Transplantation，Biospecimen Collection，Granulocyte Colony-Stimulating Factor，Hematopoietic Cell Transplantation Conditioning Regimen
地点
United States
申办方
City of Hope Medical Center
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT07012044

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

适用疾病
Acute Myeloid Leukemia Post Cytotoxic Therapy；Recurrent Acute Myeloid Leukemia；Refractory Acute Myeloid Leukemia
干预
Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Decitabine
地点
United States
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 药物手术/操作
clinicaltrials.gov NCT05554406

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

适用疾病
Acute Myeloid Leukemia；Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm；Acute Myeloid Leukemia Post Cytotoxic Therapy
干预
Azacitidine，Biospecimen Collection，Bone Marrow Aspiration，Cytarabine
地点
United States，Canada，Puerto Rico
申办方
National Cancer Institute (NCI)
即将招募 Phase 2 药物
clinicaltrials.gov NCT07493408

Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML

适用疾病
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)；Blastic Transformation of Chronic Myeloid Leukemia；Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)
干预
Asciminib add-on，Imatinib，Dasatinib，Nilotinib
地点
Hong Kong
申办方
The University of Hong Kong
正在招募 EARLY / Phase 1 器械药物
clinicaltrials.gov NCT06398457

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

适用疾病
Hematologic Malignancy；Bone Marrow Transplant Rejection；Acute Myeloid Leukemia (AML)
干预
Darzalex Faspro (Daratumumab and hyaluronidase-fihj)，JH-DSA Semi-Quant Screen and Response Score
地点
United States
申办方
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT07028073

A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia

适用疾病
Acute Myeloid Leukemia With T(8;21)(Q22;Q22)；Acute Myeloid Leukemia With T(16;16)(P13;Q22)；KIT Gene Mutation
干预
Group A (FIT): Avapritinib + IA regimen，Group B (UNFIT): Avapritinib + VA regimen
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT04010877

Multiple CAR-T Cell Therapy Targeting AML

适用疾病
Acute Myeloid Leukemia
干预
CLL-1, CD33 and/or CD123-specific CAR gene-engineered T cells
地点
China
申办方
Shenzhen Geno-Immune Medical Institute
正在招募 Phase 2 生物制剂药物放疗
clinicaltrials.gov NCT07566377

Cord Blood Transplantation in Children and Young Adults With Blood Cancer

适用疾病
Acute Myelogenous Leukemia；Acute Lymphoblastic Leukemia；Myelodysplastic Syndromes
干预
Cord Blood Units，Total Body Irradiation，Cyclophosphamide，Fludarabine
地点
United States
申办方
Memorial Sloan Kettering Cancer Center
正在招募 Phase 2 药物
clinicaltrials.gov NCT07672262

VA Consolidation in Intermediate-Risk AML

适用疾病
Acute Myeloid Leukemia；Intermediate Risk Acute Myeloid Leukemia；Consolidation Therapy
干预
Venetoclax and Azacitidine，Cytarabine ± Anthracycline
地点
China
申办方
The First Affiliated Hospital of Soochow University
即将招募 Phase 2 药物手术/操作
clinicaltrials.gov NCT07153497

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

适用疾病
Acute Myeloid Leukemia；Myelodysplastic Syndrome
干预
Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy，Decitabine and Cedazuridine
地点
未列出
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 药物
clinicaltrials.gov NCT06660368

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

适用疾病
Relapsed or Refractory Acute Myeloid Leukemia (AML)
干预
Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen，Venetoclax
地点
United States
申办方
H. Lee Moffitt Cancer Center and Research Institute
正在招募 Phase 1 药物
clinicaltrials.gov NCT04260022

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

适用疾病
Leukemia, Myeloid, Chronic；Myeloid Leukemia；Chronic Myeloid Leukemia
干预
Ascentage Pharma HQP1351 bioavailable inhibitor，Blinatumomab
地点
United States，Canada
申办方
Ascentage Pharma Group Inc.
正在招募 Phase 1 药物
clinicaltrials.gov NCT07320235

Imetelstat Combinations in Relapsed AML

适用疾病
Relapsed Acute Myeloid Leukemia
干预
Imetelstat，Azacitidine，Venetoclax
地点
United States
申办方
Douglas Tremblay
即将招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT07372885

GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia

适用疾病
Acute Myeloid Leukemia；Stem Cell Transplantation；Stem Cell Transplantation, Hematopoietic
干预
Cord blood transplantation + conditioning + granulocytes of variable days according to study design
地点
United Kingdom
申办方
University of Manchester
正在招募 Phase 2 药物
clinicaltrials.gov NCT06232655

Cladribine Venetoclax in Monocytic AML

适用疾病
Acute Myeloid Leukemia
干预
Cladribine，Venetoclax，Azacitidine
地点
United States
申办方
University of Colorado, Denver
正在招募 阶段未标明 药物手术/操作
clinicaltrials.gov NCT07588360

Haplo-Cord HSCT for AML/MDS

适用疾病
MDS (Myelodysplastic Syndrome)；AML (Acute Myeloid Leukemia)
干预
haplo-cord HSCT，Fludarabine, Cytarabine, Busulfan, Antithymocyte Globulin (ATG), Melphalan, Cyclophosphamide (CTX)
地点
China
申办方
Fujian Medical University Union Hospital
即将招募 阶段未标明 药物手术/操作
clinicaltrials.gov NCT07443592

Treatment for Ph-negative ALL for Adults up to 65 Years

适用疾病
Acute Lymphoblastic Leukemia
干预
Pediatric-type of chemotherapy (+blinatumomab for B-cell precursor ALL)，Transplantation
地点
Spain
申办方
PETHEMA Foundation
正在招募 Phase 3 生物制剂
clinicaltrials.gov NCT07441291

CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT

适用疾病
B ALL；Allogenetic Hematopoietic Stem Cell Transplantation；MRD-positive
干预
CAR-T，DLI
地点
China
申办方
Peking University People's Hospital
正在招募 Phase 3 生物制剂
clinicaltrials.gov NCT06381817

Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients

适用疾病
Acute T Cell Lymphoblastic Leukemia；Haploidentical Hematopoietic Stem Cell Transplantation；Cord Blood
干预
Haplo-cord HCT，Haplo-HCT
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 EARLY / Phase 1 生物制剂其他手术/操作
clinicaltrials.gov NCT06735690

Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia

适用疾病
Acute Lymphoblastic Leukemia
干预
Allogeneic Hematopoietic Stem Cell Transplantation，Anti-CD19-CAR CMV-specific T-lymphocytes，Biospecimen Collection，Bone Marrow Aspiration
地点
United States
申办方
City of Hope Medical Center
即将招募 Phase 1 药物
clinicaltrials.gov NCT07674823

Phase 1 Study Of KITE-753 in R/R B-Cell ALL

适用疾病
B-cell Acute Lymphoblastic Leukemia
干预
KITE-753
地点
United States
申办方
M.D. Anderson Cancer Center
正在招募 Phase 3 生物制剂
clinicaltrials.gov NCT04094311

Study of Out of Specification for Tisagenlecleucel

适用疾病
B-cell Acute Lymphoblastic Leukemia；Diffuse Large B-cell Lymphoma
干预
CTL019
地点
Canada，Japan
申办方
Novartis Pharmaceuticals
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT07070323

A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies

适用疾病
T-Cell Acute Lymphocytic Leukemia；Acute Lymphoblastic Leukemia, in Relapse；Refractory Acute Lymphoblastic Leukemia
干预
Autologous CD5 CAR T-cells，Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells，Newly matched donor-derived CD5 CAR T-cells
地点
China
申办方
Beijing GoBroad Hospital
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT06918431

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

适用疾病
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；Lymphoblastic Lymphoma
干预
Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Bone Marrow Aspiration，Bone Marrow Biopsy
地点
United States
申办方
City of Hope Medical Center
即将招募 EARLY / Phase 1 药物
clinicaltrials.gov NCT07256353

Allogeneic UCB-derived CAR-T for B-ALL

适用疾病
B-Cell Acute Lymphoblastic Leukemia, Adult
干预
allogeneic umbilical cord blood-derived CAR-T
地点
China
申办方
The General Hospital of Western Theater Command
正在招募 Phase 3 药物
clinicaltrials.gov NCT07152041

Newly-diagnosed Pediatric Ph-positive B-ALL Protocol

适用疾病
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)；Childhood Leukemia, Acute Lymphoblastic
干预
olverembatinib
地点
China，Hong Kong
申办方
Institute of Hematology & Blood Diseases Hospital, China
正在招募 Phase 1 生物制剂
clinicaltrials.gov NCT07108868

A Phase I Dose Finding Study of MB-CART2219.1

适用疾病
Lymphoma；CLL；Acute Lymphoblastic Leukemia, Pediatric
干预
CAR-T cells targeting CD19 and CD22
地点
Germany
申办方
University Hospital Tuebingen
即将招募 Phase 2, Phase 3 联合产品药物其他
clinicaltrials.gov NCT07297914

Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

适用疾病
Acute Lymphoblastic Leukemia (ALL)；Stem Cell Transplant；Graft -Versus-host-disease
干预
Total Body Irradiation 8 Gy，Ruxolitinib，Blinatumomab，Cyclophosphamide
地点
Austria，Czechia，Denmark，Finland 等 5 个
申办方
Bambino Gesù Hospital and Research Institute
正在招募 Phase 2 药物
clinicaltrials.gov NCT06561074

A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)

适用疾病
T-cell Acute Lymphoblastic Leukemia；T-Cell Lymphoblastic Lymphoma
干预
Decitabine，Venetoclax，Calaspargase pegol-mknl
地点
United States
申办方
M.D. Anderson Cancer Center
正在招募 阶段未标明 手术/操作
clinicaltrials.gov NCT07059624

Femoral Arterial Cannulation in Pediatrics

适用疾病
Pediatric ALL；Cardiac Complication；Anesthesia
干预
"Modified Dynamic Needle Tip Positioning, Short-Axis, Out-Of-Plane" (MDNTP-SAOP)，"Conventional, Short-Axis, Out-Of-Plane" (C-SAOP)
地点
Lebanon
申办方
American University of Beirut Medical Center
正在招募 Phase 2 生物制剂
clinicaltrials.gov NCT04276870

Orphan Indications for CD19 Redirected Autologous T Cells

适用疾病
Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL；Infants With Very High Risk KMT2A B-ALL；Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation
干预
Murine CART19
地点
United States
申办方
Stephan Grupp MD PhD
即将招募 Phase 2 药物
clinicaltrials.gov NCT07301424

Subcutaneous Blinatumomab Plus Ponatinib for BCR-ABL+ B-ALL

适用疾病
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)；BCR-ABL Positive Acute Lymphoblastic Leukemia
干预
Treatment with blinatumomab given subcutaneously.
地点
Canada
申办方
University of Alberta
正在招募 Phase 1 生物制剂
clinicaltrials.gov NCT06445803

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

适用疾病
Acute Lymphoblastic Leukemia, in Relapse；Acute Lymphoblastic Leukemia With Failed Remission；B-cell Lymphoma Refractory
干预
KQ-2002 CAR-T cells （CD19/CD22 CAR T-Cells）
地点
China
申办方
Rong Tao
正在招募 Phase 1, Phase 2 基因治疗
clinicaltrials.gov NCT06533579

Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)

适用疾病
B-cell Acute Lymphoblastic Leukemia；Large B-cell Lymphoma；Chronic Lymphocytic Leukemia
干预
Dose Level 1, VNX-101，Dose Level 2, VNX-101，Dose Level 3, VNX-101，Dose Level 4, VNX-101
地点
United States
申办方
Vironexis Biotherapeutics Inc.
正在招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT05674175

Co-administration of CART22-65s and huCART19 for B-ALL

适用疾病
B-cell Acute Lymphoblastic Leukemia；B Lineage Lymphoblastic Lymphoma
干预
Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)，Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
地点
United States
申办方
Stephan Grupp MD PhD
正在招募 Phase 2 药物
clinicaltrials.gov NCT06336395

Ma-Spore ALL 2020 Study

适用疾病
B Lymphoblastic Leukemia
干预
Prednisolone，Dexamethasone，Vincristine，Methotrexate
地点
Malaysia，Singapore
申办方
National University Hospital, Singapore
即将招募 阶段未标明 生物制剂
clinicaltrials.gov NCT07412405

This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R

适用疾病
Adult B-cell Acute Lymphoblastic Leukemia；Follicular Lymphoma (FL)；Mantle Cell Lymphoma (MCL)
干预
ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T)
地点
未列出
申办方
GUSTAVO SALGUERO
正在招募 Phase 1, Phase 2 生物制剂药物
clinicaltrials.gov NCT06364423

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

适用疾病
Leukemia, Lymphocytic, Chronic, B-Cell；B-Lymphocytic Leukemia, Chronic；B-Cell Chronic Lymphocytic Leukemia
干预
Autologous HuCD19 ( Anti-CD19)CAR T cells，Cyclophosphamide，Fludarabine，Rituximab
地点
United States
申办方
National Cancer Institute (NCI)
即将招募 EARLY / Phase 1 药物
clinicaltrials.gov NCT07277504

Autologous Bedside CD19 CAR T-cell Therapy for B-ALL

适用疾病
B-Cell Acute Lymphoblastic Leukemia, Adult
干预
CD19 CAR T cells
地点
China
申办方
The General Hospital of Western Theater Command
即将招募 Phase 2 药物
clinicaltrials.gov NCT07227584

ALL Backbone in AYAs

适用疾病
Acute Lymphoblastic Leukemia；Philadelphia Chromosome-Negative Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia (ALL)
干预
Blinatumomab，Oncaspar，Cyclophosphamide，Cytarabine
地点
未列出
申办方
Dana-Farber Cancer Institute
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT07224100

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

适用疾病
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1；B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1；Lymphoblastic Lymphoma
干预
Cyclophosphamide，Doxorubicin，Etoposide，Filgrastim
地点
United States
申办方
University of Washington
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT05745714

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

适用疾病
Acute Lymphoblastic Leukemia, in Relapse；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
干预
Ruxolitinib，Venetoclax，Dexamethasone，Cyclophosphamide
地点
Austria，Belgium，Denmark，Finland 等 10 个
申办方
Princess Maxima Center for Pediatric Oncology
正在招募 阶段未标明 药物手术/操作
clinicaltrials.gov NCT07454226

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

适用疾病
Ph-Like；Acute Lymphoblastic Leukemia
干预
Olverembatinib，Gecacitinib，Venetoclax，Chemotherapy Regimen
地点
China
申办方
Institute of Hematology & Blood Diseases Hospital, China
正在招募 阶段未标明 药物
clinicaltrials.gov NCT05657652

CAV Regimen for R/R Ph- B-ALL

适用疾病
Acute Lymphoblastic Leukemia
干预
cladribine, cytarabine,venetoclax
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 1 药物
clinicaltrials.gov NCT06060782

Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine

适用疾病
Burkitt Lymphoma；Lymphoblastic Lymphoma, Adult；Acute Lymphoblastic Leukemia, Adult
干预
Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
地点
China
申办方
Fifth Affiliated Hospital, Sun Yat-Sen University
正在招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT06764238

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

适用疾病
Acute Lymphoblastic Leukemia ALL；Childhood Leukemia, Acute Lymphoblastic；B Cell Acute Lymphoblastic Leukemia (B-ALL)
干预
Blinatumomab (Group A)，Venetoclax (nonRand Group)，Blinatumomab (Group B)
地点
China，Hong Kong
申办方
Institute of Hematology & Blood Diseases Hospital, China
正在招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT06874946

Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

适用疾病
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma；T - Cell Lymphoma；PTCL
干预
CD5-targeted CAR-T cells
地点
China
申办方
Peking University People's Hospital
即将招募 Phase 1 生物制剂
clinicaltrials.gov NCT07113496

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

适用疾病
Relapsed or Refractory B-cell Hematologic Malignancies；B-cell Acute Lymphoblastic Leukemia (B-ALL)；Multiple Myeloma (MM)
干预
Allogeneic CAR-T
地点
China
申办方
The First Affiliated Hospital with Nanjing Medical University
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT05658640

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

适用疾病
Acute Lymphoblastic Leukemia, in Relapse；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
干预
Trametinib，Dexamethasone，Cyclophosphamide，Cytarabine
地点
Austria，Belgium，Denmark，Finland 等 11 个
申办方
Princess Maxima Center for Pediatric Oncology
正在招募 Phase 2, Phase 3 药物其他
clinicaltrials.gov NCT06860269

A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia

适用疾病
Acute Lymphoblastic Leukemia
干预
Randomization + Blinatumomab + chemotherapy，Randomization + Standard frontline T-ALL chemotherapy backbone，Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone，Randomization + Blinatumomab + Ponatinib + chemotherapy
地点
France
申办方
Assistance Publique - Hôpitaux de Paris
正在招募 Phase 2, Phase 3 生物制剂药物
clinicaltrials.gov NCT03937544

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

适用疾病
Relapsed B Acute Lymphoblastic Leukaemia；Refractory B Acute Lymphoblastic Leukaemia
干预
CD19 CAR-T CELLS，Cyclophosphamide，Fludarabine
地点
Malaysia
申办方
National University of Malaysia
正在招募 Phase 2 器械药物
clinicaltrials.gov NCT04746209

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

适用疾病
B-cell Acute Lymphoblastic Leukemia；B-cell Childhood Acute Lymphoblastic Leukemia；B-Cell ALL, Childhood
干预
Alpha/Beta T-cell and B-cell depleted HCT，Blinatumomab
地点
United States
申办方
Medical College of Wisconsin
正在招募 Phase 2 药物
clinicaltrials.gov NCT06742463

VHAG in Treating R/R T-ALL/LBL

适用疾病
Acute T Lymphpblastic Leukemia/Lymphoma
干预
Venetoclax，homoharringtonine，Cytarabine (Ara-C)，G-CSF
地点
China
申办方
First Affiliated Hospital of Zhejiang University
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT07133997

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

适用疾病
Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预
Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Blinatumomab，Bone Marrow Aspiration
地点
United States
申办方
City of Hope Medical Center
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT05751044

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

适用疾病
Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent
干预
Dasatinib，Venetoclax，Dexamethasone，Cyclophosphamide
地点
Austria，Belgium，Denmark，Finland 等 10 个
申办方
Princess Maxima Center for Pediatric Oncology
正在招募 Phase 1 生物制剂
clinicaltrials.gov NCT07300683

Anti-CCR9 CAR T Cells for T Cell Leukaemia/Lymphoma

适用疾病
T Cell Acute Lymphoblastic Leukemia；T Cell Lymphoblastic Lymphoma
干预
CARCCR9 T cells
地点
United Kingdom
申办方
University College, London
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT05310591

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

适用疾病
B Acute Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia, in Relapse
干预
Decreasing starting times for beginning nivolumab (Time to Event Continual Reassessment Method (TITE-CRM) )，Nivolumab starting at day -1
地点
France
申办方
Assistance Publique - Hôpitaux de Paris
正在招募 Phase 1 生物制剂药物
clinicaltrials.gov NCT07066397

A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALL

适用疾病
Acute Lymphoblastic Leukemia
干预
ARM011，Fludarabine，Cyclophosphamide
地点
Taiwan
申办方
TriArm Therapeutics (Taiwan) Limited
即将招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT07387926

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

适用疾病
Acute Lymphoblastic Leukemia；Leukemia, Lymphoblastic, Acute, Philadelphia-Positive；Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
干预
Asciminib Adult formulation，Asciminib Pediatric formulation，Dexamethasone，Vincristine
地点
未列出
申办方
Novartis Pharmaceuticals
正在招募 Phase 1 药物
clinicaltrials.gov NCT05581030

CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

适用疾病
Acute Lymphoblastic Leukemia
干预
Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)，Calaspargase Pegol，Rituximab
地点
United States
申办方
H. Lee Moffitt Cancer Center and Research Institute
正在招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT06855810

Newly-diagnosed Pediatric T-cell ALL Protocol

适用疾病
Acute Lymphoblastic Leukemia；Childhood Leukemia, Acute Lymphoblastic；T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
干预
Venetoclax，Dasatinib，homoharringtonine
地点
China，Hong Kong
申办方
Institute of Hematology & Blood Diseases Hospital, China
正在招募 Phase 2 药物
clinicaltrials.gov NCT05909059

CAR T-cell Therapy in Patients With Renal Dysfunction

适用疾病
Non-hodgkin Lymphoma,B Cell；Multiple Myeloma；Acute Lymphoblastic Leukemia, Adult
干预
Fludarabine，Cyclophosphamide
地点
United States
申办方
Northside Hospital, Inc.
正在招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT04016129

CAR-T Immunotherapy Targeting CD19- ALL

适用疾病
B-cell Leukemia
干预
4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR
地点
China
申办方
Shenzhen Geno-Immune Medical Institute
正在招募 Phase 1, Phase 2 药物手术/操作
clinicaltrials.gov NCT04315324

Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)

适用疾病
Recurrent T Acute Lymphoblastic Leukemia；Refractory T Acute Lymphoblastic Leukemia；Refractory T Lymphoblastic Lymphoma
干预
AKR1C3-activated Prodrug AST-3424，Biopsy Procedure，Biospecimen Collection，Bone Marrow Aspiration
地点
United States
申办方
SWOG Cancer Research Network
即将招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT07636564

Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment

适用疾病
Acute Leukemia of Ambiguous Lineage；B Acute Lymphoblastic Leukemia；B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
干预
Biospecimen Collection，Blinatumomab，Bone Marrow Aspiration，Bone Marrow Biopsy
地点
未列出
申办方
SWOG Cancer Research Network
即将招募 阶段未标明 手术/操作
clinicaltrials.gov NCT06741813

Allo-HSCT vs ASCT in Adult T-LBL

适用疾病
T Lymphoblastic Lymphoma
干预
ASCT，Allo-HSCT
地点
未列出
申办方
Peking University People's Hospital
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT06738368

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

适用疾病
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；T Acute Lymphoblastic Leukemia
干预
Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Bone Marrow Collection，Computed Tomography
地点
United States
申办方
University of Washington
即将招募 Phase 1, Phase 2 器械药物
clinicaltrials.gov NCT07175415

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

适用疾病
Acute Lymphoblastic Leukemia；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent；Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
干预
Capivasertib，Venetoclax，Dexamethasone，Intrathecal chemotherapy
地点
未列出
申办方
Princess Maxima Center for Pediatric Oncology
正在招募 阶段未标明 基因治疗
clinicaltrials.gov NCT07371403

MB-CART19.1 in Relapsed/Refractory Acute Lymphoblastic Leukemia

适用疾病
Acute Lymphoblastic Leukemia；Acute Lymphoblastic Leukemia Recurrent；Acute Lymphoblastic Leukemia Refractory
干预
MB-CART19.1
地点
Jordan
申办方
King Hussein Cancer Center
即将招募 Phase 3 生物制剂
clinicaltrials.gov NCT06673459

BuCy Vs. TBICy for Allo-HSCT in T-ALL Patients

适用疾病
T-Cell Lymphocytic Leukemia；ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION；Total Body Irradiation
干预
TBICy，BuCy
地点
China
申办方
The First Affiliated Hospital of Soochow University
即将招募 阶段未标明 药物
clinicaltrials.gov NCT06763302

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

适用疾病
B Cell Precursor Acute Lymphoblastic Leukemia；Pediatric；Minimal Residual Disease
干预
Blinatumomab
地点
未列出
申办方
The Children's Hospital of Zhejiang University School of Medicine
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT06316856

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

适用疾病
T-Cell Acute Lymphocytic Leukemia；Acute Lymphoblastic Leukemia, in Relapse；Refractory Acute Lymphoblastic Leukemia
干预
Autologous CD5 CAR T-cells，Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells，Newly matched donor-derived CD5 CAR T-cells
地点
China
申办方
Beijing GoBroad Hospital
正在招募 Phase 1 药物
clinicaltrials.gov NCT07350863

U69-CART-Cells For R/R T-ALL

适用疾病
Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
干预
CXCR4 CCR9 CAR-T
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 阶段未标明 生物制剂
clinicaltrials.gov NCT06866873

CD-19 CAR-T Cell for Pediatric ALL or Lymphoma

适用疾病
Lymphoma, B-Cell；Acute Lymphoblastic Leukemia, Pediatric
干预
CAR-T
地点
Hong Kong
申办方
Hong Kong Children's Hospital
正在招募 阶段未标明 生物制剂
clinicaltrials.gov NCT05620680

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

适用疾病
T Lymphoblastic Leukemia/Lymphoma
干预
CD7 CAR-T cells
地点
China
申办方
Shenzhen University General Hospital
正在招募 Phase 2 药物
clinicaltrials.gov NCT06712121

Venetoclax and Decitabine in R/R T-ALL

适用疾病
T Lymphoblastic Leukemia/Lymphoma
干预
decitabine plus venetoclax
地点
South Korea
申办方
Seoul National University Hospital
即将招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT06703216

Pre-emptive Anakinra for Cytokine Event Reduction

适用疾病
B-Acute Lymphoblastic Leukemia；CAR-T Cell Therapy；Cytokine Release Syndrome
干预
Anakinra (Kineret®)
地点
United States
申办方
Ann & Robert H Lurie Children's Hospital of Chicago
正在招募 Phase 2 药物
clinicaltrials.gov NCT06099366

Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children

适用疾病
Lymphoblastic Leukemia in Children
干预
induction: vincristine, L-asparaginase, dexamethasone, intrathecal Ara-C, intrathecal Methotrexate，Consolidation: Vincristine, Mecaptopurine, Intrathecal Methotrexate，Consolidation: Vincristine, Mecaptopurine, Cyclophosphamide, Cytarabine, L-asparaginase, Intrathecal Methotrexate，Interim Maintenance(IM): Vincristine, Methotrexate, Intrathecal Methotrexate
地点
South Korea
申办方
Hee Young Ju
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT04544592

UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL

适用疾病
B-cell Acute Lymphoblastic Leukemia；B-cell Non Hodgkin Lymphoma
干预
CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells
地点
United States
申办方
University of Colorado, Denver
正在招募 Phase 2, Phase 3 药物
clinicaltrials.gov NCT06882057

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

适用疾病
Acute Lymphoblastic Leukemia ALL；Childhood Leukemia, Acute Lymphoblastic；B Cell Acute Lymphoblastic Leukemia (B-ALL)
干预
Blinatumomab，Reinduction-2 omission，Chemo-light Maintenance 2
地点
China，Hong Kong
申办方
Institute of Hematology & Blood Diseases Hospital, China
正在招募 Phase 1, Phase 2 生物制剂药物其他
clinicaltrials.gov NCT01371630

Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

适用疾病
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1；B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；Burkitt-Like Lymphoma With 11q Aberration
干预
Blinatumomab，Cyclophosphamide，Cytarabine，Dexamethasone
地点
United States
申办方
M.D. Anderson Cancer Center
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT06287229

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

适用疾病
Relapsed/Refractory；B-cell Acute Lymphocytic Leukemia
干预
Blinatumomab，Inotuzumab Ozogamicin，Hyper-CVAD，Mini-hyper-CVD
地点
United States
申办方
M.D. Anderson Cancer Center
正在招募 Phase 2 药物
clinicaltrials.gov NCT05289687

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

适用疾病
T-cell Acute Lymphoblastic Leukemia
干预
Daratumumab / Hyaluronidase Injection，Daratumumab / Hyaluronidase Injection，Daratumumab / Hyaluronidase Injection，Daratumumab / Hyaluronidase Injection
地点
United States
申办方
Eastern Cooperative Oncology Group
正在招募 Phase 3 联合产品
clinicaltrials.gov NCT05029531

Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)

适用疾病
Acute Lymphoblastic Leukemia, Pediatric；ALL, Infants
干预
the risk-adapted choice of therapy and the use of a combination of chemotherapy with immunotherapy and hematopoietic stem cell transplantation for patients with risk factors.
地点
Russia
申办方
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT07070219

A Study of CTD402 in T-ALL/LBL Patients

适用疾病
Acute Lymphocytic Leukemia Refractory；Lymphoma, Lymphoblastic
干预
CTD402 CAR T Cell Injection
地点
United States
申办方
BIOHENG THERAPEUTICS US LLC
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT04546399

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

适用疾病
Down Syndrome；Recurrent B Acute Lymphoblastic Leukemia
干预
3-Dimensional Conformal Radiation Therapy，Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Blinatumomab
地点
United States，Australia，Canada，Puerto Rico
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT06124157

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

适用疾病
B Acute Lymphoblastic Leukemia
干预
Biospecimen Collection，Blinatumomab，Bone Marrow Biopsy，Calaspargase Pegol
地点
United States，Australia，Canada，Puerto Rico
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

适用疾病
Acute Leukemia of Ambiguous Lineage；B Acute Lymphoblastic Leukemia
干预
Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Blinatumomab，Bone Marrow Aspiration
地点
United States，Puerto Rico
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 生物制剂药物
clinicaltrials.gov NCT03136146

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

适用疾病
Recurrent Acute Lymphoblastic Leukemia；Recurrent Adult Lymphoblastic Lymphoma；Recurrent Burkitt Leukemia
干预
Bortezomib，Clofarabine，Cyclophosphamide，Dexamethasone
地点
United States
申办方
M.D. Anderson Cancer Center
即将招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT07678307

A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

适用疾病
T-Cell Acute Lymphoblastic Leukemia；T-Lymphoblastic Lymphoma；Relapsed/Refractory Hematologic Malignancies
干预
Autologous nano CD5-CAR T Cells
地点
未列出
申办方
Institute of Hematology & Blood Diseases Hospital, China
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT03739814

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

适用疾病
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative；Recurrent B Acute Lymphoblastic Leukemia；Refractory B Acute Lymphoblastic Leukemia
干预
Biospecimen Collection，Blinatumomab，Bone Marrow Aspiration，Bone Marrow Biopsy
地点
United States，Puerto Rico
申办方
National Cancer Institute (NCI)
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT02981628

Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia

适用疾病
Recurrent B Acute Lymphoblastic Leukemia；Recurrent B Lymphoblastic Lymphoma；Refractory B Acute Lymphoblastic Leukemia
干预
Asparaginase Erwinia chrysanthemi，Biospecimen Collection，Bone Marrow Aspiration and Biopsy，Calaspargase Pegol
地点
United States，Puerto Rico
申办方
Children's Oncology Group
正在招募 Phase 2 药物
clinicaltrials.gov NCT05168930

Zanubrutinib and Venetoclax in CLL (ZANU-VEN)

适用疾病
Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)
干预
Venetoclax，Zanubrutinib
地点
United States
申办方
Dana-Farber Cancer Institute
即将招募 Phase 3 药物
clinicaltrials.gov NCT07516093

Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL

适用疾病
B-cell Lymphoma；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预
NX-5948，Pirtobrutinib
地点
未列出
申办方
Nurix Therapeutics, Inc.
正在招募 Phase 3 药物
clinicaltrials.gov NCT05645107

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

适用疾病
Hypogammaglobulinemia；Bacterial Infections；B-cell Chronic Lymphocytic Leukemia
干预
Xembify，Placebo
地点
United States，Bosnia and Herzegovina，Bulgaria，Croatia 等 4 个
申办方
Grifols Therapeutics LLC
正在招募 Phase 2 药物手术/操作
clinicaltrials.gov NCT04941716

Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial

适用疾病
Recurrent Chronic Lymphocytic Leukemia；Recurrent Small Lymphocytic Lymphoma；Refractory Chronic Lymphocytic Leukemia
干预
Acalabrutinib，Venetoclax，Biospecimen Collection，Bone Marrow Aspiration
地点
United States
申办方
Fred Hutchinson Cancer Center
正在招募 Phase 2 药物
clinicaltrials.gov NCT06958705

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

适用疾病
Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
干预
Venetoclax combined with Ibrutinib，Venetoclax combined with Zanubrutinib，Venetoclax combined with Acalabrutinib，Venetoclax combined with Orelabrutinib
地点
China
申办方
The First Affiliated Hospital with Nanjing Medical University
正在招募 Phase 2 药物
clinicaltrials.gov NCT04560322

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

适用疾病
Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预
Venetoclax，Obinutuzumab，Acalabrutinib
地点
United States
申办方
Massachusetts General Hospital
正在招募 Phase 3 药物
clinicaltrials.gov NCT06943872

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

适用疾病
Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预
Sonrotoclax，Obinutuzumab，Rituximab，Venetoclax
地点
United States，Argentina，Australia，Austria 等 17 个
申办方
BeOne Medicines
即将招募 Phase 1 药物
clinicaltrials.gov NCT07424833

A Study of APG-3288 in Relapsed/Refractory Blood Cancers

适用疾病
Relapsed/Refractory Hematological Malignancies；Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL；Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL; Including Richter Transformation)
干预
APG-3288
地点
United States，China
申办方
Ascentage Pharma Group Inc.
即将招募 Phase 1 药物
clinicaltrials.gov NCT07511426

U96-CAR-T-Cells For R/R B-ALL

适用疾病
Relapsed or Refractory B Cell Leukemia and Lymphoma
干预
U96
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 1, Phase 2 生物制剂
clinicaltrials.gov NCT04186520

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

适用疾病
Non Hodgkin Lymphoma (NHL)；Mantle Cell Lymphoma (MCL)；Chronic Lymphocytic Leukemia (CLL)
干预
8/12-Day Production of Car-T Cells，8/12-Day Production of Cryopreserved Car-T Cells，12-Day Production of Car-T Cells
地点
United States
申办方
Medical College of Wisconsin
正在招募 Phase 3 药物
clinicaltrials.gov NCT01804686

A Long-term Extension Study of PCI-32765 (Ibrutinib)

适用疾病
Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma；Mantle Cell Lymphoma
干预
Ibrutinib
地点
United States，Argentina，Australia，Belgium 等 26 个
申办方
Janssen Research & Development, LLC
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT06191887

B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

适用疾病
B-Cell Non-Hodgkin Lymphoma；Recurrent Chronic Lymphocytic Leukemia；Recurrent Diffuse Large B-Cell Lymphoma
干预
Autologous BAFFR-targeting CAR T Cells，Bendamustine，Biopsy，Biospecimen Collection
地点
United States
申办方
Mayo Clinic
正在招募 Phase 1, Phase 2 药物
clinicaltrials.gov NCT07052695

Mosunetuzumab for CLL MRD Clearance

适用疾病
Leukemia；Chronic Lymphocytic Leukemia；Small Lymphocytic Lymphoma
干预
Mosunetuzumab，Ibrutinib，Acalabrutinib，Zanubrutinib
地点
United States
申办方
Inhye Ahn
正在招募 Phase 1 生物制剂药物
clinicaltrials.gov NCT05963217

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

适用疾病
Relapsed or Refractory CD19+ B-cell Lymphoma；Relapsed or Refractory Chronic Lymphocytic Leukemia；Relapsed or Refractory Small Lymphocytic Lymphoma
干预
TBI-2001，Cyclophosphamide，Fludarabine
地点
Canada
申办方
University Health Network, Toronto
正在招募 Phase 1 药物
clinicaltrials.gov NCT05131022

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

适用疾病
Chronic Lymphocytic Leukemia (CLL)；Small Lymphocytic Lymphoma (SLL)；Diffuse Large B Cell Lymphoma (DLBCL)
干预
NX-5948
地点
United States，France，Italy，Netherlands 等 4 个
申办方
Nurix Therapeutics, Inc.
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT06839053

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

适用疾病
Chronic Lymphocytic Leukemia；Mantle Cell Lymphoma；Recurrent Chronic Lymphocytic Leukemia
干预
Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography，Gastrointestinal Endoscopy
地点
United States
申办方
Fred Hutchinson Cancer Center
正在招募 Phase 1 药物
clinicaltrials.gov NCT05544019

Study of SGR-1505 in Mature B-Cell Neoplasms

适用疾病
Mature B-Cell Neoplasm；Non Hodgkin Lymphoma；DLBCL
干预
SGR-1505
地点
United States，France，Italy，Moldova 等 4 个
申办方
Schrödinger, Inc.
正在招募 Phase 1 药物
clinicaltrials.gov NCT05512390

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

适用疾病
Diffuse Large B-Cell Lymphoma；Chronic Lymphocytic Leukemia；Follicular Lymphoma
干预
ABBV-319
地点
United States，Australia，Canada，Israel 等 2 个
申办方
AbbVie
正在招募 Phase 2 生物制剂药物手术/操作
clinicaltrials.gov NCT05873712

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

适用疾病
Recurrent Transformed Chronic Lymphocytic Leukemia；Refractory Transformed Chronic Lymphocytic Leukemia；Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
干预
Biospecimen Collection，Bone Marrow Biopsy，Computed Tomography，Cyclophosphamide
地点
United States
申办方
Aseel Alsouqi
正在招募 Phase 3 生物制剂药物
clinicaltrials.gov NCT05947851

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

适用疾病
Leukemia, Lymphocytic, Chronic, B-Cell；Leukemia, Chronic Lymphocytic；Small-Cell Lymphoma
干预
Nemtabrutinib，Venetoclax，Rituximab
地点
United States，Argentina，Australia，Belgium 等 14 个
申办方
Merck Sharp & Dohme LLC
正在招募 Phase 3 药物
clinicaltrials.gov NCT06104566

Global Trial in APG2575 for Patients With CLL/SLL

适用疾病
CLL/SLL
干预
lisaftoclax +BTK inhibitor，BTK inhibitor
地点
United States，Australia，Belgium，Bulgaria 等 15 个
申办方
Ascentage Pharma Group Inc.
正在招募 Phase 1 生物制剂药物手术/操作
clinicaltrials.gov NCT04892277

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

适用疾病
Recurrent B-Cell Non-Hodgkin Lymphoma；Recurrent Chronic Lymphocytic Leukemia；Recurrent Small Lymphocytic Lymphoma
干预
Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563，Bendamustine，Biospecimen Collection，Bone Marrow Aspiration
地点
United States
申办方
Mayo Clinic
正在招募 Phase 1 生物制剂
clinicaltrials.gov NCT03829540

CD4CAR for CD4+ Leukemia and Lymphoma

适用疾病
T-cell Lymphoma；T-cell Leukemia
干预
CD4CAR
地点
United States
申办方
Huda Salman
正在招募 Phase 1 药物手术/操作
clinicaltrials.gov NCT05549661

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

适用疾病
Recurrent Chronic Myelomonocytic Leukemia；Refractory Chronic Myelomonocytic Leukemia；Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
干预
Biospecimen Collection，Bone Marrow Aspiration and Biopsy，Onvansertib，Ultrasound Imaging
地点
United States
申办方
Mayo Clinic
正在招募 Phase 1 药物
clinicaltrials.gov NCT07270770

BY002 IIT Study in R/R Acute Leukemia

适用疾病
Acute Leukemia；KMT2A Rearrangements or NPM1 Mutations Acute Leukemia
干预
BY002
地点
China
申办方
The First Affiliated Hospital of Soochow University
正在招募 Phase 1 药物
clinicaltrials.gov NCT05010005

A Study of Ruxolitinib and Duvelisib in People With Lymphoma

适用疾病
T-cell Lymphomas；NK-Cell Lymphomas；T-cell Prolymphocytic Leukemia
干预
Ruxolitinib，Duvelisib
地点
United States
申办方
Memorial Sloan Kettering Cancer Center
正在招募 EARLY / Phase 1 生物制剂药物
clinicaltrials.gov NCT06756321

A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy

适用疾病
Relapsed/refractory Lymphoma；Relapsed/Refractory Leukemia
干预
anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells，Fludarabine，Cyclophosphamide
地点
China
申办方
Affiliated Hospital of Nantong University
第 1 页

Subtypes

建议拆分方向

AMLALLCLLCMLrelapsed refractory leukemiaMRDFLT3IDH1 / IDH2BCR-ABLCAR-T

Keywords

英文搜索关键词

leukemia AML acute myeloid leukemia ALL acute lymphoblastic leukemia CLL chronic lymphocytic leukemia CML chronic myeloid leukemia relapsed refractory leukemia FLT3 leukemia IDH leukemia MRD leukemia

Keyword guide

这些关键词怎么理解

术语中文意思对找临床试验有什么用
AML 急性髓系白血病。 海外 AML 试验常按 FLT3、IDH、TP53、既往治疗等拆分。
ALL 急性淋巴细胞白血病。 可以找 B-ALL、T-ALL、CAR-T、bispecific antibody 等方向。
CLL 慢性淋巴细胞白血病。 常见方向包括 BTK inhibitor、BCL2 inhibitor、复发难治等。
CML 慢性髓性白血病，常与 BCR-ABL 融合相关。 可以找 BCR-ABL、TKI resistant、T315I 等相关试验。
MRD 微小残留病灶，表示治疗后仍可检测到少量病变细胞。 部分试验会要求 MRD 阳性或以 MRD 作为观察指标。
Relapsed / refractory 复发或难治。 很多白血病新药和细胞治疗试验会限定 R/R 患者。

Recruitment status

常见招募状态

Recruiting正在招募，可能仍可申请参加。
Not yet recruiting尚未开始招募，可关注后续开放时间。
Active, not recruiting试验仍在进行，但通常不再招新患者。
Completed试验已经完成。
Terminated试验提前终止。
Unknown公开页面上的状态不明确或未及时更新。

Before contact

联系前准备资料

  • 病理诊断报告
  • 影像报告：CT / MRI / PET-CT
  • 既往治疗记录
  • 用药历史
  • 基因检测报告
  • 最近血液检查结果
  • 出院小结
  • 主治医生英文病情摘要，如果有
  • 护照和签证情况，如果考虑出国

Filters

搜索时重点关注

  • Recruiting / Not yet recruiting
  • Location
  • Age
  • Phase
  • Inclusion Criteria
  • Exclusion Criteria
  • Prior treatments
  • Biomarker / mutation requirements
  • ECOG performance status
  • 是否接受 international patients
  • 是否需要长期停留在试验所在地
  • 费用、保险、翻译、住宿和陪护安排

Ask your doctor

可以带去问医生的问题

  • 我的病理类型是否符合这个试验？
  • 我之前用过的药会不会影响入组？
  • 我是否需要做基因检测？
  • 这个试验是几期？主要目的是什么？
  • 参加试验会不会影响当前治疗？
  • 如果去国外参加，风险和成本大概有哪些？
  • 研究团队是否接受海外患者？
下一步提示

请将检索到的临床试验信息带给主治医生或肿瘤科医生讨论。本站不判断患者是否适合任何临床试验。